✦ LIBER ✦

The potential benefits of participating in early-phase clinical trials in multiple myeloma: long-term remission in a patient with relapsed multiple myeloma treated with 90 cycles of lenalidomide and bortezomib

✍ Scribed by Paul G. Richardson; Jacob P. Laubach; Robert L. Schlossman; Irene M. Ghobrial; Katherine C. Redman; Mary Mckenney; Diane Warren; Kimberly Noonan; Laura Lunde; Deborah Doss; Kathleen Colson; Teru Hideshima; Constantine Mitsiades; Nikhil C. Munshi; Kenneth C. Anderson

Book ID: 114795684
Publisher: John Wiley and Sons
Year: 2012
Tongue: English
Weight: 74 KB
Volume: 88
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.2012.01765.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

The relationship between quality of resp

The relationship between quality of response and clinical benefit for patients treated on the bortezomib arm of the international, randomized, phase 3 APEX trial in relapsed multiple myeloma

✍ Ruben Niesvizky; Paul G. Richardson; S. Vincent Rajkumar; Morton Coleman; Laura 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 245 KB

Long-term follow-up on overall survival

Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma

✍ Dimopoulos, M A; Chen, C; Spencer, A; Niesvizky, R; Attal, M; Stadtmauer, E A; P 📂 Article 📅 2009 🏛 Nature Publishing Group 🌐 English ⚖ 164 KB

Clinical efficacy of a bortezomib, cyclo

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

✍ Yeo-Kyeoung Kim; Sang-Kyun Sohn; Jae-Hoon Lee; Deok-Hwan Yang; Joon-Ho Moon; Jae 📂 Article 📅 2009 🏛 Springer 🌐 English ⚖ 175 KB

Achievement of at Least Very Good Partia

Achievement of at Least Very Good Partial Response Is a Simple and Robust Prognostic Factor in Patients With Multiple Myeloma Treated With High-Dose Therapy: Long-Term Analysis of the IFM 99-02 and 99-04 Trials

✍ Harousseau, J.-L.; Avet-Loiseau, H.; Attal, M.; Charbonnel, C.; Garban, F.; Huli 📂 Article 📅 2009 🏛 American Society of Clinical Oncology 🌐 English ⚖ 236 KB

Long-term efficacy and safety of zoledro

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma : A randomized, double-blind, multicenter, comparative trial

✍ Lee S. Rosen; David Gordon; Mary Kaminski; Anthony Howell; Andrew Belch; John Ma 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 2 views

## Abstract ## BACKGROUND The goal of the current study was to compare the long‐term (25‐month) safety and efficacy of zoledronic acid with pamidronate in patients with bone lesions secondary to advanced breast carcinoma or multiple myeloma. ## METHODS Patients (__n__ = 1648) were randomized to